Analyst consensus rating
Ultragenyx Pharmaceutical Analyst Rating: Buy
Direct answer
Ultragenyx Pharmaceutical's consensus rating is Buy.
19 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $27.00.
Forecast evidence checked September 16, 2026.
Get free Ultragenyx Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.07
- Average price target
- $27.00
- High price target
- $40.00
- Low price target
- $16.00
- Low target gap
- +22.4%
- Target upside
- +106.6%
- High target gap
- +206%
- Target range width
- 183.6%
- Consensus rating
- Buy
- Analysts
- 19
- Evidence date
- September 16, 2026
- Valid through
- September 23, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a verified Buy consensus. The same dataset has an average price target of $27.00.
How far are Ultragenyx Pharmaceutical's low and high targets from the recorded price?
The low target implies +22.4%, while the high target implies +206%.
How many analysts are included in Ultragenyx Pharmaceutical's consensus?
The verified consensus includes 19 analysts.
How is Ultragenyx Pharmaceutical's target upside or downside calculated?
The average target of $27.00 is divided by the recorded price of $13.07, then one is subtracted to produce +106.6%. This does not guarantee a future return.
When was Ultragenyx Pharmaceutical's analyst forecast verified?
The data was verified on 2026-09-16. The dataset is valid through 2026-09-23.